Risks Associated with COVID-19 Infection and Vaccination for Headache Disorders
Very little is known about the effect of any COVID-19 vaccine on cluster headache. What little research we have has been done on migraine and tension-type headache. We don’t have answers to all the questions. That doesn’t mean we don’t know anything.Read More →
Assessment of immunogenicity from galcanezumab phase 3 trials in patients with episodic or chronic migraine
This analysis characterizes the immunogenicity profile of galcanezumab, a humanized monoclonal antibody that selectively binds calcitonin gene-related peptide and inhibits its activity, in phase 3 migraine trials.Read More →
Refractory short-lasting unilateral neuralgiform headache attacks with conjunctival injection and tearing responsive to anti-calcitonin gene-related peptide monoclonal antibodies: A case report
Short-lasting unilateral neuralgiform headache attacks with conjunctival injection and tearing (SUNCT) is a rare but severely disabling variant within the spectrum of trigeminal autonomic cephalalgia lacking evidence-based treatment.Read More →
Effect of calcitonin gene-related peptide (-receptor) antibodies in chronic cluster headache: Results from a retrospective case series support individual treatment attempts
CGRP has an important pathophysiological role in cluster headache. Chronic cluster headache patients with insufficient response to other preventive treatments have been receiving individual off-label treatment attempts with CGRP antibodies.Read More →
Targeting CGRP for the Prevention of Migraine and Cluster Headache: A Narrative Review
Calcitonin-gene-related peptide (CGRP), a neuropeptide broadly distributed in neuronal and non-neuronal regions throughout the body, plays a fundamental role in migraine and cluster headache (CH) pathophysiology.Read More →
CGRP, a target for preventive therapy in migraine and cluster headache: Systematic review of clinical data
Targeting the calcitonin gene-related peptide (CGRP) pathway to treat these headaches may be the first focused therapeutic option to date, with the potential for promising efficacy.Read More →